Skip to main content
. Author manuscript; available in PMC: 2019 Dec 1.
Published in final edited form as: Leukemia. 2019 May 24;33(12):2805–2816. doi: 10.1038/s41375-019-0491-z

Figure 2. Assessment of ONC212 potency in AML cells.

Figure 2.

(A) Summary data of ONC212’s effects on several AML cell lines at the indicated concentration for 72 h. (B) The percentage of apoptotic cells induced by ONC212 treatment for 120 h in KG-1, HL-60, U937, Kasumi-1, and THP-1 cell lines. (C) Time course analysis of apoptosis induced by ONC212 or ONC201 in OCI-AML3 cells. (D) Time course analysis of the percentage of live cells following treatment with ONC212 or ONC201. Annexin V- and PI-negative cells were counted as live cells. (E) The percentage of apoptotic cells induced by ONC212 treatment for 72 h in parental or ONC201-resistant (ONC-R) OCI-AML3 cells. (F) The percentage of live cell numbers after 72 h-treatment with ONC212 in parental or ONC-R OCI-AML3 cells. The percentage of AnnexinV+ cells of MV4;11 (G) and MOLM13 (H) cells treated with ONC212 (250 nM) for 4, 8, 24, 36, and 72 h. ONC212 medium was replaced by fresh medium at these time points and cell viability was determine at 72 h for all samples. Data are shown as the mean ± SD (n = 3). **; p < 0.01, ***; p < 0.005.